Charles Dadswell Sells 5.4k Illumina Shares in $1.2 Million Form 144 Filing
2h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
illuminaform-144
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A Form 144 filing with the Securities and Exchange Commission on June 6, 2026, disclosed that Illumina director Charles Dadswell intends to sell 5,452 shares of the gene sequencing company. The shares are valued at approximately $1.2 million based on Illumina's closing price of $221.55 on June 5, the day before the filing was submitted. The filing represents a routine plan by a non-executive director to dispose of vested stock, not an open-market transaction.
Form 144 filings are required notices of intent to sell restricted or control securities. They provide a scheduled window for executives and directors to sell shares, often under pre-arranged 10b5-1 trading plans. These plans are designed to prevent accusations of insider trading by executing trades on a predetermined schedule.
This sale follows several years of significant insider activity at Illumina. In late 2023 and early 2024, following the contentious acquisition and subsequent divestiture of Grail, multiple senior executives executed substantial sales. The current filing occurs as Illumina navigates a pivotal period for its core business and legal obligations.
The timing coincides with the healthcare sector facing macroeconomic headwinds. The iShares Biotechnology ETF (IBB) is down 4% year-to-date, underperforming the S&P 500's 8% gain. High interest rates continue to pressure the valuations of life science companies dependent on long-term R&D investment cycles.
The filing pertains to 5,452 shares of Illumina common stock. At the June 5 closing price of $221.55, the block carries a dollar value of $1,207,488. The sale, if fully executed, will reduce Dadswell's direct holdings by a material portion.
Illumina's stock performance provides critical context. The share price is down 18% over the past 12 months. This decline contrasts with a 10% gain for the broader Nasdaq Biotechnology Index over the same period. The company's current market capitalization stands near $35 billion.
A comparison of insider selling volumes shows relative stability. The three-month average of Form 144 filings for Illumina insiders is approximately $2.5 million in disclosed intended sales. The current $1.2 million filing is slightly below this recent average.
| Metric | Value |
|---|---|
| Shares to Sell | 5,452 |
| Price per Share (June 5 Close) | $221.55 |
| Total Intended Sale Value | ~$1.2 million |
| Illumina 12-Month Performance | -18% |
| Nasdaq Biotech Index 12-Month Performance | +10% |
The sale is a routine portfolio rebalancing event from a board member, not a signal of corporate distress. Directors typically hold a large portion of their net worth in company stock and use planned sales for liquidity and diversification. The transaction size represents a minor fraction of Illumina's average daily trading volume of $250 million.
Second-order effects are limited, but the filing keeps investor focus on Illumina's governance and capital allocation. It may prompt scrutiny of similar activity at peer firms like Thermo Fisher Scientific (TMO) and Pacific Biosciences (PACB), where insider selling trends are also monitored as sentiment indicators.
A significant counter-argument is that non-executive director sales carry less informational weight than those of the CEO or CFO. These individuals have less granular, day-to-day operational insight. The primary market risk for Illumina remains its commercial execution and the ongoing legal challenges related to the Grail saga, not director stock plans.
Positioning data from options markets shows a slight increase in short-term put option volume for Illumina, indicating some investors are hedging against near-term volatility. Equity flow data does not show a corresponding surge in outright short selling following the Form 144 disclosure.
The immediate catalyst is the execution window for this sale. Form 144 filings allow sales to occur within 90 days, providing a near-term overhang of up to $1.2 million in potential selling pressure. The actual market impact will depend on how the sales are structured and executed.
Investors will monitor Illumina's second-quarter 2026 earnings report, expected in late July. Key metrics will include sequencing instrument placements, consumables revenue growth, and any updates on the final resolution of the Grail divestiture and associated legal fines.
Technical levels to watch include Illumina's 200-day moving average, currently near $235, which has acted as resistance. A sustained break above this level could signal improving technical momentum, while failure to hold support around $215 may indicate continued weakness.
A Form 144 is a mandatory notice filed with the SEC by corporate insiders, typically officers, directors, or major shareholders, indicating their intent to sell restricted or control securities. The filing is required when the sale amount exceeds certain thresholds within a three-month period. It signals a planned transaction but does not guarantee the sale will be completed. The rule aims to ensure transparency and prevent insider trading by making these planned dispositions public.
Charles Dadswell's intended $1.2 million sale is modest relative to historical transactions by Illumina executives. In early 2024, following the Grail divestiture announcement, several C-suite executives sold shares valued at over $5 million each under 10b5-1 plans. The volume of total insider selling at Illumina has decreased significantly from the peak observed during the height of the Grail-related corporate uncertainty in 2023.
Academic studies show a weak correlation between routine director selling and future underperformance, especially when trades are made under pre-set 10b5-1 plans. The signal is considered stronger when multiple executives sell large portions of their holdings simultaneously outside of such plans. For Illumina, the more significant performance drivers are product cycle momentum, competitive dynamics with BGI Group, and resolution of regulatory penalties.
A director's planned $1.2 million stock sale is a routine liquidity event, not a fundamental signal for Illumina's struggling gene sequencing business.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.